France offers two complementary incentives for companies with intellectual property and research activities: the Research Tax Credit (Crédit d'Impôt Recherche, CIR), which provides a 30% credit on eligible R&D expenses up to EUR 100 million (Article 244 quater B of the Code Général des Impôts, CGI), and the IP Box regime, which applies a reduced 10% corporate tax rate to net income derived from qualifying patents and similar rights (Article 238 CGI). Both regimes interact with France's standard corporate income tax rate of 25%, and each carries its own eligibility conditions, documentation requirements, and audit exposure. Understanding how to claim these reliefs correctly – and how to defend a claim under scrutiny – is essential for any international business operating in France.
| Regime | Rate / Benefit | Legal Basis | Key Threshold |
|---|---|---|---|
| Research Tax Credit (CIR) | 30% tax credit on eligible R&D expenses | Art. 244 quater B CGI | Up to EUR 100 million of eligible expenses |
| IP Box | 10% rate on net qualifying IP income | Art. 238 CGI | Qualifying patents and similar rights |
| Standard CIT | 25% on taxable profit | Art. 219 CGI | General rate; all entities |
| SME reduced rate | 15% on first EUR 42,500 of profit | Art. 219 CGI | Turnover under EUR 10 million |
Legal Framework and Policy Context
The CIR is one of the most significant tax structuring tools available to companies investing in research and development in France. Enacted through Article 244 quater B CGI, it was designed to make France a competitive location for R&D activities by allowing eligible expenditure – including researchers' salaries, subcontracting costs, and amortisation of dedicated assets – to generate a direct offset against corporate income tax liability.
The IP Box, governed by Article 238 CGI, was redesigned to comply with the OECD's modified nexus approach, which conditions preferential treatment on a genuine economic link between the qualifying income and the R&D activities that created the underlying IP. This nexus requirement is central to tax risk management: groups that hold IP in France without conducting meaningful local research may find that their claimed income fails the nexus calculation and is taxed at the standard 25% rate rather than 10%.
Both regimes sit alongside France's general anti-avoidance rules, including the acte anormal de gestion doctrine and statutory provisions targeting artificial arrangements. The interaction between the CIR, the IP Box, and intra-group transfer pricing policies requires careful calibration, particularly where R&D is performed by a French entity on behalf of a foreign principal.
The CIR in Practice: Step-by-Step Procedure
Claiming the CIR is procedurally straightforward, but the substantive qualification of expenses is where most disputes arise. The following steps reflect the standard process.
- Step 1 – Identify eligible expenses. The CGI defines a specific list of qualifying costs. These typically include wages and social charges for researchers and technicians, depreciation of assets exclusively used for research, costs of subcontracted R&D (with specific caps and conditions applying to subcontracting to related parties), and certain intellectual property and patent costs. Expenditure must relate to activities meeting the OECD's Frascati criteria for basic research, applied research, or experimental development.
- Step 2 – Prepare technical documentation. Each project claimed must be documented with a technical file describing the scientific or technical uncertainty addressed, the systematic approach taken, and the qualifications of personnel involved. This file is the primary document reviewed during a tax audit by the Direction Générale des Finances Publiques (DGFiP) and, where technical questions arise, by the Ministère chargé de la Recherche.
- Step 3 – Declare the credit on the annual return. The CIR is declared on Form 2069-A-SD, submitted with the annual corporate tax return. The credit offsets the company's CIT liability; where the credit exceeds the tax due, the balance may be carried forward for three years and then refunded, or – for SMEs, newly incorporated companies, and certain other entities – claimed as an immediate cash refund.
- Step 4 – Consider an advance ruling. France's rescrit fiscal procedure allows companies to obtain a binding opinion from the DGFiP on whether a planned R&D programme qualifies for the CIR before the expenditure is incurred. For significant investments, this is an important risk-management step. Our guide on advance tax rulings in France explains the procedure in detail.
- Step 5 – Maintain ongoing records. Documentation must be maintained for the duration of the applicable limitation period. The DGFiP has the authority to reassess CIR claims and may request the technical ministry's opinion on the scientific validity of claimed projects; that opinion, once issued, is binding on the tax authority.
If your company is in the process of designing or reviewing its R&D cost allocation, we are available to discuss the structuring considerations. Please contact us at info@ferrazwhitmore.com or visit our contacts page.
The IP Box: Qualifying Income, the Nexus Requirement, and Transfer Pricing
The French IP Box taxes net income derived from qualifying intellectual property at 10% rather than the standard 25% rate. Qualifying assets include patents granted by a competent authority, utility certificates, and – subject to conditions – certain software protected by copyright where it results from genuine R&D work. Pure trademarks, marketing intangibles, and customer lists are excluded.
Net income under the regime is calculated by reference to the qualifying income (royalties, capital gains on qualifying IP, and notional income where IP is exploited internally) less directly attributable costs. The nexus fraction then applies: only the proportion of net income attributable to R&D expenditure incurred by the taxpayer itself (or by unrelated third parties on its behalf) qualifies for the reduced rate. R&D expenditure outsourced to related parties reduces the nexus fraction, creating a direct incentive to conduct research within the French entity.
For international groups, the interface between the IP Box and transfer pricing documentation obligations is significant. Where a French entity licenses IP to or from related parties, the arm's-length pricing of those transactions will directly affect both the quantum of qualifying income and the nexus calculation. France's transfer pricing documentation rules require large groups to maintain a master file and a local file, and to complete the country-by-country reporting obligations applicable to groups above the relevant consolidated revenue threshold. Discrepancies between the transfer pricing analysis and the IP Box computation are a recurring focus of DGFiP audits.
Our tax structuring practice in France regularly advises on the interaction between IP ownership structures, the nexus requirement, and intra-group pricing policies. Early-stage planning, before IP is developed or transferred, significantly broadens the options available.
Common Errors by Foreign Clients
Companies approaching the CIR and IP Box from outside France frequently encounter the same difficulties. Being aware of these patterns allows them to be addressed proactively.
- Treating the CIR as automatic. The 30% credit is not granted on the basis of registration alone. It requires that the activities claimed genuinely meet the Frascati definition of R&D. Innovative product development that involves no scientific or technical uncertainty will not qualify, regardless of the cost involved.
- Insufficient technical files. Foreign clients often underestimate the depth of scientific justification the DGFiP and the research ministry expect. Files that describe commercial objectives rather than scientific methodology are regularly challenged.
- Subcontracting to related parties without applying the statutory caps. The CGI imposes specific limits on the eligible cost of R&D subcontracted to related entities. Exceeding these caps – or failing to document that the counterparty itself conducted the research – is a frequent cause of reassessment.
- IP Box claims without nexus analysis. Booking royalty income in France and applying 10% without performing or documenting the nexus fraction calculation is one of the highest-risk positions a company can take. The DGFiP has made IP box compliance a priority area.
- Overlooking the interaction with tax treaties. Where royalties flow between France and another jurisdiction, the applicable tax treaty may affect withholding tax obligations and the overall effective rate. Treaty benefits do not automatically apply; the conditions must be met and, in some cases, demonstrated proactively to the paying entity.
- Late or incomplete rescrit requests. Companies that invest in R&D programmes without obtaining a prior ruling and then face a tax audit lose the certainty and negotiating position that an advance ruling would have provided. The rescrit procedure has defined timescales that must be respected.
Realistic Timelines and Cost Drivers
The CIR credit is declared annually with the corporate tax return. The timeline from incurring eligible expenditure to recovering a refund (where no tax liability exists to offset) depends on the entity's status: SMEs and certain other qualifying entities may obtain an immediate refund on filing, while standard entities carry the credit forward and recover it through offset or, after the carry-forward period, cash refund.
A rescrit on CIR eligibility is subject to a defined response period under French administrative procedure; where no response is received within that period, the absence of a reply is treated as a positive outcome under the applicable silence-is-consent rules. However, a substantive response – particularly where technical questions are referred to the research ministry – may take longer, and any planned R&D timeline should accommodate this.
In the event of a tax audit, the DGFiP may open a full verification of accounts or a more limited documentary examination. The duration varies depending on the complexity of the claim and the availability of documentation. Disputes that are not resolved at the administrative stage may proceed through the French courts, ultimately reaching the Cour de cassation on questions of law. Litigation timelines in France are measured in years rather than months; maintaining robust documentation from the outset is the most effective way to contain this risk.
The principal cost drivers for CIR and IP Box compliance are: the time of qualified research personnel needed to produce and maintain technical files; external advisers engaged to review eligibility and prepare documentation; and, where a rescrit is sought, the preparation of the ruling request. For groups undergoing structural change – through acquisition, reorganisation, or the transfer of IP – additional costs arise from the need to reanalyse nexus fractions and update transfer pricing documentation.
Decision Checklist: Is Your Company Well-Positioned?
Before committing to a CIR claim or restructuring around the IP Box, the following questions provide a practical starting framework.
- Does the R&D activity involve a genuine scientific or technical uncertainty that cannot be resolved by applying existing knowledge?
- Are the researchers and technicians carrying out the work based in France, and are their employment and project records adequate?
- Is the IP held in the entity that conducted the qualifying research, or has it been transferred? If transferred, at what value and under what conditions?
- Has the nexus fraction been calculated, documented, and reviewed in the context of the group's transfer pricing policy?
- Does the applicable tax treaty with the ultimate parent's jurisdiction affect the treatment of royalties or the availability of the IP Box benefit?
- Have any anti-avoidance rules – including the EU Anti-Tax Avoidance Directives as implemented in France – been assessed for their potential application to the structure?
- Is a rescrit appropriate given the scale and novelty of the R&D programme?
- Is the company's corporate governance and legal structuring in France consistent with the substance requirements of both regimes? Our corporate law practice in France can assist with reviewing the legal structure of the French entity.
Audit Risk and Dispute Management
Both the CIR and the IP Box are subject to active scrutiny by the DGFiP. The tax authority has developed significant expertise in assessing the technical validity of R&D claims, and increasingly coordinates with the research ministry on scientific questions. Companies that have relied on CIR claims as a routine budget item – without maintaining contemporaneous documentation – are particularly exposed when a verification is opened.
Where a reassessment notice (proposition de rectification) is issued, the company has the right to respond within the statutory period, and the administrative dialogue that follows is frequently the most effective forum in which to resolve disputed points. If the matter proceeds further, it may involve the DGFiP's internal conciliation procedures, and ultimately the Cour de cassation on points of law. Engaging a lawyer France with specific experience in tax litigation alongside the group's tax advisers is advisable from the point at which a verification is opened.
For companies that have already received a reassessment or are under active audit in relation to CIR or IP Box claims, please contact our team at info@ferrazwhitmore.com or through our contacts page to discuss how we can assist.
Sources
PwC Tax Summaries – France (Corporate: Taxes on Corporate Income): https://taxsummaries.pwc.com/france/corporate/taxes-on-corporate-income. Facts last verified: 22 September 2026.
If you are assessing whether your current R&D and IP structure in France is optimised, or whether existing claims are defensible under audit, our team at Ferraz & Whitmore would be pleased to discuss your situation. Reach us at info@ferrazwhitmore.com or via our contacts page.
Disclaimer: This publication is provided for informational purposes only and does not constitute legal advice. The information herein should not be relied upon as a substitute for professional legal counsel tailored to your specific circumstances. Ferraz & Whitmore assumes no liability for actions taken or not taken based on the contents of this material. For advice regarding your particular situation, please contact info@ferrazwhitmore.com.